At the intersection of genomics and mental health, researchers at Mount Sinai have taken a careful step toward a more precise understanding of psychiatric risk — not by making grand claims, but by demonstrating that something practical is possible. By reaching into a diverse urban biobank to find and recontact individuals carrying rare genetic variants linked to autism, intellectual disability, and schizophrenia, they have shown that targeted psychiatric research can be conducted within real healthcare systems, with real populations, at meaningful scale. The work is less a breakthrough than a